Brief: Halozyme Therapeutics, Chugai Pharmaceutical Enter Global Collaboration And License Agreement For Enhanze Technology
24/03/2022 12:55
March 24 (Reuters) - Chugai Pharmaceutical Co Ltd 4519.T :
* HALOZYME THERAPEUTICS, INC. AND CHUGAI PHARMACEUTICAL
ENTER
GLOBAL COLLABORATION AND LICENSE AGREEMENT FOR ENHANZE®
TECHNOLOGY
* HALOZYME THERAPEUTICS INC - CHUGAI WILL MAKE AN UPFRONT
PAYMENT
OF $25 MILLION TO HALOZYME
* HALOZYME THERAPEUTICS INC - IS OBLIGATED TO MAKE POTENTIAL
FUTURE PAYMENTS OF UP TO $160 MILLION
Source text for Eikon: ID:nPnc0nz9Fa
Further company coverage: 4519.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)